 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 GLOBE NEWSWIRE -- Lyell Immunopharma, Inc. Lyell, Nasdaq: LYEL, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today reported financial results for the second quarter and first six months of 2021 and provided business highlights. 